The Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) test, powered by CSIR-IGIB (Institute of Genomics and Integrative Biology) FELUDA, received regulatory approvals today from the Drug Controller General of India (DCGI) for commercial launch, as per ICMR guidelines, meeting high quality benchmarks with 96% sensitivity and 98% specificity for detecting the novel coronavirus.
Daily Current Affairs Quiz 2020
Key-Points
This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus.
CRISPR is a genome editing technology for diagnosing diseases. The Tata CRISPR test is the world’s first diagnostic test to deploy a specially adapted Cas9 protein to successfully detect the virus causing Covid-19.
The Tata CRISPR test achieves accuracy levels of traditional RT-PCR tests, with quicker turnaround time, less expensive equipment, and better ease of use.
The Tata Group has worked closely with CSIR-IGIB and ICMR to create this high-quality test.
